We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Allakos Inc
6 own
12 watching
Current Price
$7.37
$0.2
(2.79%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
627.87M
52-Week High
8.73
52-Week Low
2.535
Average Volume
0.49M
Dividend Yield
--
P/E Ratio
--
Market Capitalization627.87M52-Week High8.7352-Week Low2.535Average Volume0.49MDividend Yield--P/E Ratio--What does the Allakos Inc do?
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Read More
How much money does Allakos Inc make?
News & Events about Allakos Inc.
Zolmax
2 months ago
Allakos Inc. (NASDAQ:ALLK Get Rating) Equities researchers at Jefferies Financial Group lifted their FY2022 EPS estimates for Allakos in a note issued to investors on Monday, November 7th. Jefferies Financial Group analyst M. Raycroft now expects that the company will post earnings per share of ($5....
Globe Newswire
2 months ago
Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells AK007 potently blocks all known ligand interaction with Siglec-10, including the dont eat me signal CD24 Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-...
PR Newswire
4 months ago
Thinking about buying stock in Purple Innovation, Knowbe4, Allakos, Larimar Therapeutics, or Alzamend Neuro? Thinking about buying stock in Purple Innovation, Knowbe4, Allakos, Larimar Therapeutics, or Alzamend Neuro? PR Newswire NEW YORK, Sept. 19, 2022 NEW YORK, Sept. 19, 2022 /PRNewswire...
Globe Newswire
4 months ago
Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and ...
Ticker Report
4 months ago
Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Allakos Inc. (NASDAQ:ALLK Get Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 233,600 shares of the companys stock, ...
Frequently Asked Questions
Frequently Asked Questions
What is Allakos Inc share price today?
Can Indians buy Allakos Inc shares?
How can I buy Allakos Inc shares from India?
Can Fractional shares of Allakos Inc be purchased?
What are the documents required to start investing in Allakos Inc stocks?
What is today’s traded volume of Allakos Inc?
What is today’s market capitalisation of Allakos Inc?
What is the 52-Week High and Low Range of Allakos Inc?
What percentage is Allakos Inc down from its 52-Week High?
What percentage is Allakos Inc up from its 52-Week Low?
Current Price
$7.37
$0.2
(2.79%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.